Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14274
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chittasupho C. | |
dc.date.accessioned | 2021-04-05T03:33:57Z | - |
dc.date.available | 2021-04-05T03:33:57Z | - |
dc.date.issued | 2012 | |
dc.identifier.issn | 20415990 | |
dc.identifier.other | 2-s2.0-84867940749 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/14274 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84867940749&doi=10.4155%2ftde.12.99&partnerID=40&md5=7dacdc19cbff1ce1c4410b6d7493ae1c | |
dc.description.abstract | Multivalent interactions of biological molecules play an important role in many biochemical events. A multivalent ligand comprises of multiple copies of ligands conjugated to scaffolds, allowing the simultaneous binding of multivalent ligands to multiple binding sites or receptors. Many research groups have successfully designed and synthesized multivalent ligands to increase the binding affinity, avidity and specificity of the ligand to the receptor. A multimeric ligand is a promising option for the specific treatment of diseases. In this review, the factors affecting multivalent interactions, including the size and shape of the ligand, geometry and an arrangement of ligands on the scaffold, linker length, thermodynamic, and kinetics of the interactions are discussed. Examples of the multivalent ligand applications for therapeutic delivery are also summarized. © 2012 Future Science Ltd. | |
dc.subject | antibody | |
dc.subject | antibody conjugate | |
dc.subject | arginylglycylaspartic acid | |
dc.subject | cancer vaccine | |
dc.subject | carbohydrate | |
dc.subject | cephalosporin | |
dc.subject | cisplatin | |
dc.subject | cytotoxic T lymphocyte antigen 4 antibody | |
dc.subject | dendrimer | |
dc.subject | doxorubicin | |
dc.subject | ligand | |
dc.subject | macrogol | |
dc.subject | multivalent ligand | |
dc.subject | nanoparticle | |
dc.subject | peptide | |
dc.subject | polyamidoamine | |
dc.subject | polyglactin | |
dc.subject | polymer | |
dc.subject | single chain fragment variable antibody | |
dc.subject | tumor antigen | |
dc.subject | tumor vaccine | |
dc.subject | unclassified drug | |
dc.subject | very late activation antigen 4 | |
dc.subject | vitronectin receptor | |
dc.subject | autoimmune disease | |
dc.subject | binding affinity | |
dc.subject | binding site | |
dc.subject | breast cancer | |
dc.subject | cancer immunotherapy | |
dc.subject | concentration (parameters) | |
dc.subject | conformational transition | |
dc.subject | controlled drug release | |
dc.subject | density | |
dc.subject | drug delivery system | |
dc.subject | drug half life | |
dc.subject | encapsulation | |
dc.subject | enthalpy | |
dc.subject | entropy | |
dc.subject | human | |
dc.subject | IC 50 | |
dc.subject | immunogenicity | |
dc.subject | ligand binding | |
dc.subject | molecular interaction | |
dc.subject | molecularly targeted therapy | |
dc.subject | nonhuman | |
dc.subject | priority journal | |
dc.subject | protein multimerization | |
dc.subject | review | |
dc.subject | T lymphocyte activation | |
dc.subject | thermodynamics | |
dc.subject | Animals | |
dc.subject | Binding Sites | |
dc.subject | Drug Delivery Systems | |
dc.subject | Drug Design | |
dc.subject | Humans | |
dc.subject | Ligands | |
dc.subject | Thermodynamics | |
dc.title | Multivalent ligand: Design principle for targeted therapeutic delivery approach | |
dc.type | Review | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Therapeutic Delivery. Vol 3, No.10 (2012), p.1171-1187 | |
dc.identifier.doi | 10.4155/tde.12.99 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.